Demand does not create legality. A prescription does not make an ineligible active pharmaceutical ingredient (API) eligible. And a certificate of analysis, no matter how polished, does not create a lawful pathway to compound a drug.

Those distinctions matter now because peptides have moved from a niche area of integrative medicine into a major regulatory and commercial debate. Reuters reported analyst estimates of $2.2 billion to $3.3 billion for a potential market tied to expanded access to these peptides.

FDA's Pharmacy Compounding Advisory Committee (PCAC) met July 23-24, 2026, to consider seven peptide families for possible inclusion on the section 503A Bulks List:

• BPC-157
• KPV
• TB-500, the thymosin beta-4 fragment
• MOTS-c
• Emideltide, also known as delta sleep-inducing peptide or DSIP
• Epitalon
• Semax

PCAC recommended inclusion of both the free-base and acetate forms for six families: BPC-157 (8 yes, 6 no, 1 abstention), KPV (8-6-1), TB-500 (8-6-1), MOTS-c (7-5-2), Epitalon (7-4-1), and Semax (8-5-1). It recommended against both Emideltide forms (6 yes, 7 no, 1 abstention). The same tally applied to both forms within each family. These were 14 substance-specific advisory votes, not FDA approvals or permission to compound. The results may support future rulemaking, but none of the 14 substances are currently eligible for the section 503A bulks-list compounding.

In April 2026, the FDA moved these peptides out of the active Category 2 table and into a separate "Bulk drug substances nominated but withdrawn" section on the same safety-risk webpage. FDA's final 503A interim-policy guidance expressly states that withdrawal and a resulting category update do not reflect an FDA determination on the validity of a nomination or the reason for withdrawal, and FDA may continue to evaluate a withdrawn substance at its discretion. The change did not place any peptide in Category 1, add it to the final list, approve it, or authorize compounding. That is the central point being lost in much of the current peptide discussion.

Four regulatory statuses are commonly conflated. They are not equivalent "lists" and only one is codified in regulation:

The final 503A Bulks List is distinct from the three legacy nomination categories. Under FDA's January 7, 2025 guidance, substances nominated on or after that date are no longer placed into Categories 1, 2, or 3; the existing Category 1 interim policy remains available only for qualifying legacy substances.

• The final 503A Bulks List: The legally operative list is codified at 21 C.F.R. section 216.23(a) and currently contains six substances. Five are limited to topical use; Brilliant Blue G is not route-limited in the regulation. None of the 14 peptide substances reviewed in July appears on the list.
• Category 1: A legacy interim enforcement-discretion category for certain pre-January 7, 2025 nominations with sufficient support and no identified significant safety risk. It is not approval or final listing. FDA states that it does not intend to take action if all policy conditions are met, including section 510 registration for the original and all subsequent manufacturers, a valid certificate of analysis, and compliance with all other section 503A conditions.
• Category 2: A legacy category for adequately supported nominations for which FDA identified potential significant safety risks. The Category 1 enforcement policy does not apply; FDA states that it would consider action under its general enforcement policies.
• Category 3: A legacy category for nominations with insufficient information for FDA to evaluate. The Category 1 enforcement policy does not apply.

What does the favorable PCAC vote actually mean?

PCAC advises the FDA. Its recommendations are nonbinding. The committee does not approve drugs, amend federal regulations, or authorize pharmacies to begin compounding.

A favorable recommendation means FDA will consider the committee's advice. After consulting PCAC and the United States Pharmacopeia, FDA would need to use notice-and-comment rulemaking to add a substance: publish a proposed rule, allow public comment, consider the record, and publish an effective final rule amending 21 C.F.R. section 216.23. All actions that have historically taken longer than the industry would like to see.

In the absence of an effective final rule adding the exact bulk drug substance or another explicit FDA policy that squarely applies, a favorable committee vote is not a defensible "go-live" date for a pharmacy.

Even eventual addition to the Bulks List would not mean:

• The peptide is FDA-approved
• FDA has approved every promoted indication, dose, route, or combination
• A “research use only” seller may market it for human use
• A pharmacy may ignore the remaining patient-specific, sourcing, quality, labeling, applicable complaint and adverse-event obligations, state-law, and USP requirements

FDA itself emphasized at the July meeting that compounded drugs are not FDA-approved and do not undergo premarket review for safety, effectiveness, or manufacturing quality.

Notable state regulatory actions involving peptides:

State pharmacy and professional boards can enforce their own laws and can treat noncompliance with federal compounding requirements as grounds for discipline.

• Ohio: The Ohio Board of Pharmacy has been unusually direct. Its December 2025 guidance on common prescriber-clinic and medical-spa violations states that peptides such as BPC-157 and other bulk drug substances then in Categories 2 and 3 could not be compounded and characterizes that activity as violating federal and state law. In a June 1, 2026 summary suspension and notice of opportunity for hearing involving Pure Health, the Board alleged that BPC-157 "may not be compounded or sold" because it has no applicable USP/NF monograph, is not a component of an approved drug, and is not on the final 503A Bulks List. The latter document is an administrative allegation, not a final adjudication.
• California: California Board meeting records from 2020 state that staff had confirmed with FDA that many peptides were not eligible for section 503A exemptions and that investigations would continue where appropriate. In a 2023 first amended accusation and statement of issues against Wells Pharmacy Network, the Board alleged that BPC-157 and a CJC-1295/ipamorelin combination were noncompliant bulk substances because the exact substances did not satisfy the monograph, approved-component, or final-list route. The accusation is an allegation, not a final adjudication.
• Alabama: Although it is not a board of pharmacy, the Alabama Board of Medical Examiners adopted a May 2026 notice directed to physicians and advanced-practice clinicians. In its own broad wording, the notice prohibits physicians from compounding, advising, recommending, supplying, prescribing, administering, or dispensing "non-FDA-approved or research-grade" peptides and states that no such peptide is on an approved formulary for Alabama certified nurse midwives, certified registered nurse practitioners, or physician assistants.

‍

Product quality still matters, but legality comes first

The current peptide market has generated understandable concern about material identity, assay and potency, purity, peptide-related impurities, aggregation, microbiological quality and bioburden, endotoxin, finished-product sterility where applicable, and supply-chain traceability. Those are legitimate issues. FDA's briefing materials repeatedly describe inconsistent common names, multiple salts or derivatives marketed under the same name, and the risk that the API used may not be the API prescribed.

As of July 29, 2026, none of the 14 specific bulk drug substances reviewed, the free-base and acetate forms of the seven peptide families, has:

1. An applicable USP or National Formulary drug-substance monograph
2. Status as a component of an FDA-approved drug
3. An entry in the final 503A Bulks List codified at 21 C.F.R. § 216.23

Drug products compounded from these bulk drug substances therefore do not currently satisfy section 503A(b)(1)(A)(i) and are not eligible for the section 503A exemptions. FDA's final guidance states that such compounding may violate the Federal Food, Drug, and Cosmetic Act and may be subject to enforcement action.

While much online peptide supply is labeled "research use only", even a well-characterized API manufactured under cGMP by a section 510-registered establishment and accompanied by a valid certificate of analysis is not eligible under section 503A unless it also meets one of the three statutory routes. A favorable PCAC recommendation may encourage investment in better-characterized API supply, but it does not cure the current eligibility problem.

What responsible pharmacies should do now

Pharmacies interested in this area can:

• Monitor FDA's post-meeting actions, including any proposed rule, final rule, or explicit substance-specific policy
• Prequalify the original and all subsequent API manufacturers for section 510 registration and appropriate quality systems, without purchasing clinical inventory
• Develop route- and dosage-form-specific specifications for identity, assay and potency, peptide-related impurities, aggregates, residual solvents, microbial quality and bioburden, endotoxin, particulates, and finished-product sterility where applicable
• Assess formulation, analytical-method, stability, container-closure, and cold-chain requirements
• Evaluate state-specific restrictions in every state served
• Prepare SOPs and associated compounding process controls

Pharmacies currently making or dispensing products from any of these 14 bulk drug substances should not interpret the April 2026 category update or the July votes as retroactive authorization. They should obtain qualified legal counsel, separate compliance decisions from commercial pressure, and document the statutory and policy basis for each product they continue to offer.

The bottom line

The July 2026 PCAC meeting is a major development for peptide compounding, but it is the beginning of a legal pathway, not the end of one.
In peptide compounding, source quality matters. Testing matters. Prescriber oversight matters.
But the first question must always be simpler: Is this exact bulk drug substance currently eligible for section 503A bulk compounding? As of July 29, 2026, the answer is no for all 14 specific bulk drug substances reviewed.

*This blog is for general educational purposes and reflects the regulatory record available as of July 29, 2026. It is not legal advice or medical advice. Pharmacies and prescribers should consult qualified counsel and applicable licensing authorities before acting.*

‍

‍

By Lauren Del Valle | Pharmaceuticals Advisor for Arora Health

Lauren Del Valle is a pharmacy operations leader with over a decade of experience advancing quality, compliance, and efficiency across the pharmaceutical and 503B compounding sectors. Her career spans district operations at CVS Health, strategic leadership roles within BBraun’s 503B compounding teams, and consulting work supporting high-performance, regulatory-ready pharmacy environments. She has led teams through complex operational challenges, driving improvements in SOPs, elevating cGMP compliance, and strengthening FDA, DEA, and board inspection readiness.

Known for her ability to streamline systems and inspire collaborative, growth-oriented teams, Lauren has played a key role in shaping corporate culture and operational excellence at Central Admixture Pharmacy Services, Inc. Her expertise includes 503B compounding, change management, regulatory and quality oversight, and organizational leadership within highly regulated healthcare settings.

‍